Skip to content

Net Change in Cash at other companies

Eli Lilly logo
Eli LillyLLY
-$1.99B-1,035%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$16.16M+69.2%
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
-$9.29M-52.2%
Immunome logo
ImmunomeIMNM
-$70.79M-162%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$36.04M-317%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$139.47M+442%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's net change in cash?
Perspective Therapeutics (CATX) reported net change in cash of $23.34M in Q1 2026.
How has Perspective Therapeutics's net change in cash changed year-over-year?
Perspective Therapeutics's net change in cash increased by 235.9% year-over-year, from -$17.17M to $23.34M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.